RESUMEN
The coexpression of CD5 and CD10 has previously been reported in cases of intermediate- and high-grade lymphomas and in precursor B cells in normal or regenerating bone marrow. We report 3 cases of low-grade B-cell lymphoma that were found to coexpress CD5 and CD10 at the time of initial diagnosis. The first case was classified as small lymphocytic lymphoma; the second as follicle center lymphoma, follicular grade 1; and the third as small B-cell lymphoma otherwise not specified. Currently, the clinical implication of the coexpression of CD5 and CD10 is not known. We describe this finding to highlight the difficulty that may be encountered in classifying lymphomas in cases where this coexpression is present.
Asunto(s)
Antígenos CD5/metabolismo , Linfoma de Células B/metabolismo , Linfoma de Células B/patología , Neprilisina/metabolismo , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Inmunohistoquímica , Leucemia Linfocítica Crónica de Células B/metabolismo , Leucemia Linfocítica Crónica de Células B/patología , Linfoma de Células B/clasificación , Linfoma Folicular/metabolismo , Linfoma Folicular/patología , MasculinoRESUMEN
A 63-year-old woman presented with a single plaque on her left earlobe that was shown to be a B-cell lymphoma on histopathologic examination. Immunohistochemical studies on the paraffin-embedded tissue and flow cytometry of fresh tissue helped characterize the neoplasm. She had no other systemic involvement and a diagnosis of primary cutaneous B-cell lymphoma was made. This neoplasm has, in general, a good prognosis with excellent response to radiation therapy, polychemotherapy, or both.
Asunto(s)
Oído Externo , Linfoma de Células B/diagnóstico , Neoplasias Cutáneas/diagnóstico , Diagnóstico Diferencial , Femenino , Humanos , Inmunohistoquímica , Linfoma de Células B/patología , Persona de Mediana Edad , Neoplasias Cutáneas/patologíaRESUMEN
Ten years of cumulative experience represented by 4,902 consecutive diagnostic bone-marrow examinations at a tertiary care and referral center were reviewed to assess the value of specific components. While it has been shown previously that the information obtained from each component is generally complementary, the inclusion of some or all components may vary between institutions. The components studied included aspirate smears, clot sections, biopsy cores, and touch imprints of biopsy and clot sections. Three clinical presentations accounted for the majority of cases: staging for carcinoma or lymphoma, cytopenias, and acute leukemia. We conclude that bilateral aspirates with biopsies are required for diagnosis in staging of neoplasms and that a unilateral aspirate with biopsy is sufficient to assess patients with cytopenia or leukemia. Only rarely were touch imprints of biopsy cores necessary to establish a diagnosis; however, their early availability prior to examining sections of the clot and core did provide immediate information, when positive, in the staging of patients with carcinoma. In a small percentage of staging and leukemia cases the diagnosis rested with the clot section alone. The findings in this study address common assumptions associated with routine diagnostic hematology and oncology procedures, and are important to both clinicians and pathologists concerned with accuracy, quality assurance, turnaround time, and cost containment.